Key Highlights
- President Trump issued an executive directive instructing federal health authorities to accelerate psychedelic drug approval processes, sparking a sector-wide rally.
- Enveric Biosciences (ENVB) shares skyrocketed over 160% during Monday’s trading session, positioning it as the top performer in psychedelic biotech.
- The administration announced a $50 million funding commitment for ibogaine research targeting PTSD treatment applications.
- Other psychedelic stocks rallied sharply: Compass Pathways (CMPS) climbed 26.1%, AtaiBeckley (ATAI) surged 28.1%, and GH Research (GHRS) advanced nearly 20%.
- RBC’s Brian Abrahams characterized the executive directive as “a substantial step towards diminishing regulatory risk” across the psychedelic therapeutics industry.
Shares of psychedelic biotechnology companies surged Monday following President Trump’s weekend executive directive ordering federal health authorities to expedite approval pathways for psychedelic-based medical treatments. Enveric Biosciences (ENVB) dominated the rally, closing Monday’s session with gains exceeding 160% — a remarkable performance for a company carrying a market capitalization of merely $3.43 million.
Enveric Biosciences, Inc., ENVB
The executive order took a broad approach, avoiding specific company mentions while directing the FDA and associated regulatory bodies to streamline bureaucratic processes surrounding psychedelic drug authorizations. The general nature of the directive proved sufficient to lift virtually every stock operating in this therapeutic category.
AtaiBeckley (ATAI) surged 28.1% in premarket activity. Compass Pathways (CMPS) registered a 26.1% increase. Definium Therapeutics (DFTX) posted a 14.6% gain. GH Research (GHRS) climbed 19.7%. The momentum rippled across the entire sector swiftly.
Administration Commits $50M to Ibogaine Studies
Alongside the regulatory directive, President Trump announced a $50 million federal investment dedicated to ibogaine research initiatives. Ibogaine represents a psychoactive substance extracted from African plant sources and currently maintains Schedule I classification under U.S. law — designating it as having no accepted medical application at the federal level.
This funding commitment represents a notable pivot in the administration’s approach to mental health challenges, particularly post-traumatic stress disorder. Preliminary clinical investigations have demonstrated ibogaine’s therapeutic potential for PTSD sufferers, with particular relevance for military veteran populations.
Kabir Nath, CEO of Compass, issued a public statement praising the executive directive, noting it “recognizes the profound urgency of the mental health crisis facing millions of Americans.” Brian Abrahams, analyst at RBC, reinforced this perspective, characterizing the order as “a substantial step towards diminishing regulatory risk” facing psychedelic treatment developers.
ENVB’s dramatic price movement arrived against a backdrop of recent corporate developments. The company had just completed a $5 million private financing arrangement mere days before — a capital raise that exceeded the firm’s total market valuation at that time. The offering consisted of 2,222,223 shares priced at $2.25 apiece, accompanied by two warrant series carrying a $2.00 per share exercise price.
Pipeline Assets and Intellectual Property Developments
The company’s primary development candidate, EB-003, targets both 5-HT2A and 5-HT1B receptor systems and is advancing through development for psychiatric and neurological indications. Recently disclosed mechanistic research demonstrated that EB-003 engages dual signaling cascades associated with antidepressant and anti-anxiety therapeutic effects.
ENVB also secured a U.S. patent encompassing its EVM301 molecular series, which includes EB-003, while simultaneously obtaining Canadian trademark protection for five proprietary marks including “Enveric” and “Next Generation Mental Health.”
Should warrant holders from the recent private placement exercise both series completely, the company stands to generate an additional $8.9 million in gross capital.
Monday’s extraordinary stock movement — surpassing 160% — captured both the favorable policy shift created by the executive directive and the strategic timing of recent fundraising that extended the company’s operational timeline heading into this catalytic moment.
